Aristotle
Commercial- Indications
- Multiple cancer detection
Company intelligence / Profile preview
StageZero Life Sciences offers commercialized advanced blood-based diagnostic tests—most notably Aristotle®, the first mRNA multi-cancer panel capable of detecting multiple cancers with high sensitivity/specificity from a single blood sample. The company also provides telehealth programs such as AVRT™ for risk reduction and the COC Protocol for adjunctive care in diagnosed patients. Early clinical data suggest improved outcomes in patients using these protocols.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on StageZero Life Sciences.